Vicore’s Almee Receives the US FDA’s Breakthrough Device Designation for Pulmonary Fibrosis
Shots:
- Vicore’s 9wk. digital cognitive behavioral therapy (CBT), Almee, has received the US FDA’s Breakthrough Device Designation for its use as an adjunct treatment of pulmonary fibrosis associated anxiety symptoms
- The Almee was being evaluated under the COMPANION program in participants (n=110) receiving anxiolytic or anti-depressant therapy or both and not on cognitive behavioral therapy. The study measured anxiety using instruments such as GAD-7 and quality of life using the K-BILD questionnaire
- The program depicted an improved 4.4-point K-BILD total score for quality of life and an improved 2.7-point over control in GAD-7
Ref: Vicore | Image: Vicore
Related Newswire:- Vicore and Nippon Shinyaku Collaborate for the Development and Commercialization of C21 in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
